Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors

LESSONS LEARNED. Treatment with BEZ235 has not been shown to demonstrate increased efficacy compared with everolimus and may be associated with a poorer tolerability profile. The hypothesis of dual targeting of the phosphatidylinositol 3‐kinase and mammalian target of rapamycin pathways in patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Salazar, Ramon, Garcia‐Carbonero, Rocio, Libutti, Steven K., Hendifar, Andrew E., Custodio, Ana, Guimbaud, Rosine, Lombard‐Bohas, Catherine, Ricci, Sergio, Klümpen, Heinz‐Josef, Capdevila, Jaume, Reed, Nicholas, Walenkamp, Annemiek, Grande, Enrique, Safina, Sufiya, Meyer, Tim, Kong, Oliver, Salomon, Herve, Tavorath, Ranjana, Yao, James C.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058330/
https://ncbi.nlm.nih.gov/pubmed/29242283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0144
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados